Highlights 

  • Picard Medical unveils in-vitro data for its fully implantable Emperor Total Artificial Heart at ISMCS 2025. 
  • The presentation focuses on next-generation motor-driven design with no external pneumatic driver. 
  • The new system aims to enhance patient mobility and day-to-day independence. 
  • SynCardia technology remains the only commercially available total artificial heart in the U.S. and Canada. 
  • Over 2,100 implants of SynCardia artificial hearts performed globally to date. 

Picard Medical, Inc. (NYSE:PMI), the parent company of SynCardia Systems LLC, is preparing to showcase new benchtop performance data for its fully implantable Emperor Total Artificial Heart (TAH) at the 31st Annual Meeting of the International Society for Mechanical Circulatory Support (ISMCS 2025). The event, held in Vienna, Austria from December 1–4, 2025, will gather global leaders in mechanical circulatory support technology. 
The presentation will offer an in-depth look at the Emperor TAH’s engineering advancements and its potential to reshape care for patients with end-stage heart failure. 

A Fully Implantable System Designed for Greater Patient Freedom 

The Emperor Total Artificial Heart represents SynCardia’s most ambitious step toward a fully implantable, next-generation heart replacement platform. Unlike earlier designs that require external pneumatic drivers, the Emperor uses an internal motor-driven mechanism. 
This architecture is engineered to enhance patient mobility and quality of life by removing the need for external equipment, which has historically limited patient activity. The in-vitro data to be presented at ISMCS 2025 will provide insights into the performance, efficiency, and durability of this new design. 

SynCardia’s Leadership in Artificial Heart Therapy 

Picard Medical’s subsidiary SynCardia remains an industry pioneer with the onlyFDA- and Health Canada–approved total artificial heart currently available. Its SynCardia Total Artificial Heart is widely used for patients with severe or irreversible heart failure, functioning as a full cardiac replacement system. 
More than 2,100 implants have been performed across 27 countries, making SynCardia technology the most utilized and extensively studied artificial heart solution worldwide. The company’s next-generation Emperor system builds on this deep clinical foundation while aiming to expand treatment options and improve patient outcomes. 

Conclusion 

Picard Medical’s presentation at ISMCS 2025 marks an important milestone in the evolution of total artificial heart technology. With its fully implantable design and innovative engineering, the Emperor TAH could redefine what is possible for patients requiring complete heart replacement. As SynCardia continues to push forward with advanced circulatory support solutions, the upcoming data is expected to be closely followed by clinicians, researchers, and the broader cardiovascular technology community. 

Also read - Sanofi (NASDAQ:SNY): EU Clears Dupixent as First Targeted CSU Treatment in a Decade